Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review)

Till,Kathleen J.; Coupland,Sarah E.; Pettitt,Andrew R.

doi:10.3892/ijo.2014.2395

Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review)

Authors:
- Kathleen J. Till
- Sarah E. Coupland
- Andrew R. Pettitt
View Affiliations

Affiliations: Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK
Published online on: April 23, 2014 https://doi.org/10.3892/ijo.2014.2395
Pages: 5-12

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B cell non-Hodgkin's lymphomas (B-NHLs) consist of a wide spectrum of entities and consequently have varied clinical courses. Like many other malignancies, each of the B-NHL depend on their microenvironment for growth and survival; therefore, understanding the factors involved in their tissue localisation is likely to have implications for therapies designed to treat B-NHL. This review summarises the chemokines, integrins and sphingosine-1 phosphate receptors involved in normal B cell location and distribution within the lymphoid tissues (lymph nodes, spleen and bone marrow). It also provides a précis of what is known about these factors in the disease state: i.e., in some subtypes of B-NHL.

View Figures

View References

1.	Cyster JG: Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Ann Rev Immunol. 23:127–159. 2005. View Article : Google Scholar : PubMed/NCBI
2.	von Andrian U and Mackay CR: T-cell function and migration: two sides of the same coin. N Engl J Med. 343:1020–1034. 2000.
3.	Campbell JJ and Butcher EC: Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 12:336–341. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Okada T, Ngo VN, Ekland EH, et al: Chemokine requirements for B cell entry into lymph nodes and peyers patches. J Exp Med. 196:65–75. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Matloubain M, Lo CG, Cinamon G, et al: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 427:355–360. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Lo CG, Xu Y, Proia RL and Cyster JG: Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 201:291–301. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Muller G, Hopken UE and Lipp M: The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev. 195:117–135. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Cyster JG, Ansel KM, Reif K, et al: Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev. 176:181–193. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR and Zou YR: The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med. 200:1145–1156. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Glodek AM, Honczarenko M, Le Y, Campbell JJ and Silberstein LE: Sustained activation of cell adhesion is a differentially regulated process in B lymphopoiesis. J Exp Med. 197:461–473. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Harnett MH: B cells spread and gather. Science. 312:709–710. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Laudanna C, Kim JY, Constantin G and Butcher EC: Rapid leukocyte activation by chemokines. Immunol Rev. 186:37–46. 2002. View Article : Google Scholar
13.	Ostermann G, Weber K, Zernecke A, Schroder A and Weber C: JAM-1 is a ligand of the β₂ integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 3:151–158. 2002.
14.	Shulman Z, Shinder V, Klein E, et al: Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin. Immunity. 30:384–396. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Lo CG, Lu TT and Cyster JG: Integrin-dependence of lymphocyte entry into the white pulp. J Exp Med. 197:353–361. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Cinamon G, Matloubain M, Lesneski M, et al: Sphingosine 1-phosphate receptor promotes B cell localization in the splenic marginal zone. Nat Immunol. 5:713–720. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Ryan DH, Nuccie BL, Abboud CN and Winslow JM: Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest. 88:995–1004. 1991. View Article : Google Scholar : PubMed/NCBI
18.	Gorfu G, Rivera-Nieves J and Ley K: Role of β7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med. 9:836–850. 2009.
19.	Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B and Butcher EC: Role of α₄-integrins in lymphocytes homing to mucosal tissues in vivo. J Immunol. 152:3282–3293. 1994.
20.	Rosen H and Goetzl EJ: Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 5:560–570. 2005. View Article : Google Scholar
21.	Donovan EE, Pelanda R and Torres R: S1P3 confers differential S1P-induced migration by autoreactive and non-autoreactive immature B cells and is required for normal B-cell development. Eur J Immunol. 40:688–698. 2010. View Article : Google Scholar
22.	Foucar K: B cell chronic lymphocytic and prolymphocytic leukemia. Williams and Wilkins; Baltimore: 1992
23.	Till KJ, Lin K, Zuzel M and Cawley JC: The chemokine receptor CCR7 and α4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 99:2977–2984. 2002.
24.	Shanafelt TD, Bone ND, Geyer SM, et al: Prognostic importance of CD49d expression in chronic lymphocytic leukemia. Blood. 108:786a2006.
25.	Gattei V, Bulian P, Del Principe MI, et al: High CD49d protein expression predict short overall survival and early progression in chronic lymphocytic leukemia patients. Leuk Lymph. 48(Suppl 1): S602007.
26.	Burger JA, Burger M and Kipps TJ: Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 94:3658–3667. 1999.
27.	Burger JA and Peled A: CXCR4 antagonists: targeting the micro-environment in leukemia and other cancers. Leukemia. 23:43–52. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Calissano C, Damle RJ, Hayes G, et al: In vivo intra- and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukaemia. Blood. 114:4832–4842. 2009. View Article : Google Scholar
29.	Lopez-Giral S, Quintana NE, Caberixo M, et al: Chemokine receptors that mediated B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol. 76:462–471. 2004. View Article : Google Scholar
30.	Hoellenriegel J, Meadows SA, Sivina M, et al: The phosphoinositide 3′ kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 118:3603–3612. 2011.
31.	Kinashi T: Intracellular signaling controlling integrin activation in lymphocytes. Nat Rev Immunol. 5:546–559. 2005. View Article : Google Scholar : PubMed/NCBI
32.	Sasaki AT, Chun C, Takeda K and Firtel RA: Localised Ras signaling at the leading edge regulates PI3K, cell polarity, and directional cell movement. J Cell Biol. 167:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
33.	Friedberg JW, Sharman J, Sweetenham J, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115:2578–2585. 2011. View Article : Google Scholar : PubMed/NCBI
34.	Mocsai A, Ruland J and Tybulewicz VLJ: The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 10:387–402. 2010. View Article : Google Scholar : PubMed/NCBI
35.	de Rooij MFM, Kuil A, Geest CR, et al: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 119:2590–2594. 2012.PubMed/NCBI
36.	Burger M, Hartmann T, Fujii N, Kipps TJ and Burger JA: CXCR4 chemokine receptor antagonists inhibit activation, migration, and survival of chronic lymphocytic leukemia cells in response to stromal cell-derived factor 1 (SDF-1/CXCL12). Blood. 102:15852003.
37.	Zuccchetto A, Viasitti T, Benedetti D, et al: The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia. 26:1293–1300. 2012.
38.	Mackay CR: Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol. 9:988–998. 2008. View Article : Google Scholar : PubMed/NCBI
39.	Weisberg E, Azab AK, Manley PW, et al: Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 26:985–990. 2012. View Article : Google Scholar : PubMed/NCBI
40.	Cawley JC: Hairy cell leukemia and the microenvironment. Leuk Lymph. 52(Suppl 2): S93–S95. 2011. View Article : Google Scholar
41.	Cawley JC, Zuzel M and Caligaris-Cappio F: Biology of the hairy cell. Hairy Cell Leukemia. Tallman M and Polliack A: Harwood Academic Publishers; Newark: pp. 9–18. 1999
42.	Aziz KA, Till KJ, Zuzel M and Cawley JC: Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood. 96:3161–3167. 2000.PubMed/NCBI
43.	Basso K, Liso A, Tiacci E, et al: Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 199:59–68. 2004. View Article : Google Scholar : PubMed/NCBI
44.	Potsch C, Vohringer D and Pircher H: Distinct migration patterns of naive and effector CD8 T cells in the spleen: correlation with CCR7 receptor expression and chemokine reactivity. Eur J Immunol. 29:3652–3570. 1999. View Article : Google Scholar : PubMed/NCBI
45.	Burger JA, Sivina M and Ravandi F: The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymph. 52(Suppl 2): S94–S98. 2011. View Article : Google Scholar : PubMed/NCBI
46.	Burthem J, Vincent A and Cawley JC: Integrin receptors and hairy cell leukaemia. Leuk Lymph. 21:211–215. 1996. View Article : Google Scholar : PubMed/NCBI
47.	Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM and Stetler-Stevenson M: Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. 136:625–630. 2001. View Article : Google Scholar : PubMed/NCBI
48.	Pals ST, de Gorter DJ and Spaargaren M: Lymphoma dissemination: the other face of lymphocyte homing. Blood. 110:3102–3111. 2007. View Article : Google Scholar : PubMed/NCBI
49.	Terol M-J, Lopez-Giuillermo A, Bosch F, et al: Expression of beta-integrin adhesion molecules in non-Hodgkin’s lymphoma: correlation with clinical and evolutive features. J Clin Oncol. 17:1869–1875. 1999.PubMed/NCBI
50.	Janke K, Coupland S, Na I-K, et al: Expression of the chemokine receptors CXCR4, CXCR5 and CCR7 in primary central nervous system lymphoma. Blood. 106:384–385. 2005. View Article : Google Scholar : PubMed/NCBI
51.	Cattoretti G, Mandelbaum J, Lee N, et al: Targeted disruption of the S1P₂ sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 69:8686–8692. 2009.PubMed/NCBI
52.	Lepley D, Paik J-H, Hla T and Ferrer F: The G protein-coupled receptor S1P₂ regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res. 65:3788–3795. 2005.PubMed/NCBI
53.	Klapper W: Pathobiology and diagnosis of follicular lymphoma. Semin Diagn Pathol. 28:146–160. 2011. View Article : Google Scholar : PubMed/NCBI
54.	Hopken UE, Foss HD, Meyer D, et al: Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood. 99:1109–1116. 2002. View Article : Google Scholar
55.	Coupland SE: The challenge of the microenvironmnent in B-cell lymphomas. Histopathology. 58:69–80. 2011. View Article : Google Scholar : PubMed/NCBI
56.	Wartenberg M, Vasil P, Meyer C, et al: Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse. Haematologica. 98:1433–1441. 2013. View Article : Google Scholar
57.	Gisbert J and Calvet X: Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther. 34:1047–1062. 2011.PubMed/NCBI
58.	Piris MA, Arribas A and Mollejo M: Marginal zone lymphoma. Semin Diagn Pathol. 28:135–145. 2011. View Article : Google Scholar
59.	Drillenburg P, van der Voort R, Koopman G, et al: Preferential expression of the mucosal homing receptor integrin α4β7 in gastrointestinal non-Hodgkin’s lymphomas. Am J Pathol. 150:919–927. 1997.
60.	Liu YX, Yoshino T, Ohara N, et al: Loss of expression of α4β7 integrin and L-selectin is associated with high-grade progression of low-grade MALT lymphoma. Mod Pathol. 14:798–805. 2001.
61.	Trentin L, Cabrelle A, Facco M, et al: Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood. 104:502–508. 2004. View Article : Google Scholar : PubMed/NCBI
62.	Sander B: Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin Diagn Pathol. 28:245–255. 2011. View Article : Google Scholar : PubMed/NCBI
63.	Kluin-Nelemans JC, Hoster E and Walewski J: R-CHOP Versus R-FC followed by maintenance with rituximab versus interferon-α: outcome of the first randomized Trial for elderly patients with mantle cell lymphoma. Blood. 118:4932011.
64.	Sjöberg J, Halthur C, Kristinsson SY, et al: Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973–2009. Blood. 119:990–996. 2012.PubMed/NCBI
65.	Kurtova AV, Tamayo AT, Ford RJ and Burger JA: Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 113:4604–4613. 2009. View Article : Google Scholar : PubMed/NCBI
66.	Mraz M, Zent CS, Church AK, et al: Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 155:53–64. 2011.PubMed/NCBI
67.	Geissmann F, Ruskoné-Fourmestraux A, Hermine O, et al: Homing receptor α4β7 integrin expression predicts digestive tract involvement in mantle cell lymphoma. Am J Pathol. 153:1701–1705. 1998.
68.	Del Giudice I, Messina M, Chiaretti S, et al: Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutate status of immunoglobulin heavy chain genes. Br J Haematol. 156:601–611. 2012.
69.	Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 31:88–94. 2012. View Article : Google Scholar : PubMed/NCBI
70.	Chang BY, Francesco M, De Rooij J, et al: Egress of CD19⁺CD5⁺ cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 122:2414–2422. 2013.
71.	Ferry JA: Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 11:375–383. 2006.
72.	Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG and Williams LT: A B-cell-homing chemokine made in lymphoid follicles activates Burkitt’s lymphoma receptor-1. Nature. 391:799–803. 1998.PubMed/NCBI
73.	Birkenbach M, Josefsen K, Yalamanchili R, Lenoir G and Kieff E: Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J Virol. 67:2209–2220. 1993.PubMed/NCBI
74.	Lalor S and Segal BM: Lymphoid chemokines in the CNS. J Neuroimmunol. 224:56–61. 2010. View Article : Google Scholar
75.	Pranzatelli MR, Tata ED, McGee NR, et al: Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J Neuroimmunol. 243:81–88. 2012. View Article : Google Scholar : PubMed/NCBI
76.	Rincon J, Prieto J and Patarroyo M: Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt’s lymphoma cells. Int J Cancer. 51:452–458. 1992.PubMed/NCBI
77.	Inghirami G, Grignani F, Sternas L, Lombardi L, Knowles DM and Dalla-Favera R: Down-regulation of LFA-1 adhesion receptors by c-myc oncogenie in human B lymphoblastoid cells. Science. 250:682–686. 1990. View Article : Google Scholar : PubMed/NCBI
78.	Kadin M and Rathore B: Hodgkin’s lymphoma therapy: past, present, and future. Exp Opin Pharmacother. 11:2891–2906. 2010.
79.	Steidl C, Connors JM and Gascoyne RD: Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 29:1812–1826. 2011.
80.	Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L and Poppema S: Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol. 13:52–56. 2002.
81.	Ellis PA, Hart DN, Colls BM, Nimmo JC, MacDonald JE and Angus HB: Hodgkin’s cells express a novel pattern of adhesion molecules. Clin Exp Immunol. 90:117–123. 1992.